ACAT-1-Regulated Cholesteryl Ester Accumulation Modulates Gemcitabine Resistance in Biliary Tract Cancer
Published 2022 View Full Article
- Home
- Publications
- Publication Search
- Publication Details
Title
ACAT-1-Regulated Cholesteryl Ester Accumulation Modulates Gemcitabine Resistance in Biliary Tract Cancer
Authors
Keywords
-
Journal
ANNALS OF SURGICAL ONCOLOGY
Volume -, Issue -, Pages -
Publisher
Springer Science and Business Media LLC
Online
2022-01-07
DOI
10.1245/s10434-021-11152-1
References
Ask authors/readers for more resources
Related references
Note: Only part of the references are listed.- Sterol O-Acyl Transferase 1 as a Prognostic Marker of Adrenocortical Carcinoma
- (2020) Amanda Meneses Ferreira Lacombe et al. Cancers
- Structural basis for catalysis and substrate specificity of human ACAT1
- (2020) Hongwu Qian et al. NATURE
- Structure of nevanimibe-bound tetrameric human ACAT1
- (2020) Tao Long et al. NATURE
- Proteomics identifies new therapeutic targets of early-stage hepatocellular carcinoma
- (2019) Ying Jiang et al. NATURE
- Heterogeneity of Treg/Th17 According to Cancer Progression and Modification in Biliary Tract Cancers via Self-Producing Cytokines
- (2019) Mitsuru Kinoshita et al. DIGESTIVE DISEASES AND SCIENCES
- Cholesterol esterification inhibition and gemcitabine synergistically suppress pancreatic ductal adenocarcinoma proliferation
- (2018) Junjie Li et al. PLoS One
- Hypoxia-Induced PLOD2 is a Key Regulator in Epithelial-Mesenchymal Transition and Chemoresistance in Biliary Tract Cancer
- (2018) Yuichiro Okumura et al. ANNALS OF SURGICAL ONCOLOGY
- Enhanced chemo-immunotherapy against melanoma by inhibition of cholesterol esterification in CD8+ T cells
- (2018) Man Li et al. Nanomedicine-Nanotechnology Biology and Medicine
- A Prospective, Randomized Phase II Study of Adjuvant Gemcitabine Versus S-1 After Major Hepatectomy for Biliary Tract Cancer (KHBO 1208)
- (2018) Shogo Kobayashi et al. ANNALS OF SURGERY
- Cholesterol esterification inhibition and imatinib treatment synergistically inhibit growth of BCR-ABL mutation-independent resistant chronic myelogenous leukemia
- (2017) Shovik Bandyopadhyay et al. PLoS One
- Potentiating the antitumour response of CD8+ T cells by modulating cholesterol metabolism
- (2016) Wei Yang et al. NATURE
- Abrogating cholesterol esterification suppresses growth and metastasis of pancreatic cancer
- (2016) J Li et al. ONCOGENE
- A Histone Deacetylase Inhibitor Suppresses Epithelial-Mesenchymal Transition and Attenuates Chemoresistance in Biliary Tract Cancer
- (2016) Takuya Sakamoto et al. PLoS One
- Avasimibe Encapsulated in Human Serum Albumin Blocks Cholesterol Esterification for Selective Cancer Treatment
- (2015) Steve Seung-Young Lee et al. ACS Nano
- Cholesterol uptake disruption, in association with chemotherapy, is a promising combined metabolic therapy for pancreatic adenocarcinoma
- (2015) Fabienne Guillaumond et al. PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA
- Cholesteryl Ester Accumulation Induced by PTEN Loss and PI3K/AKT Activation Underlies Human Prostate Cancer Aggressiveness
- (2014) Shuhua Yue et al. Cell Metabolism
- Cisplatin and gemcitabine for advanced biliary tract cancer: a meta-analysis of two randomised trials
- (2013) J. W. Valle et al. ANNALS OF ONCOLOGY
- miR-320c regulates gemcitabine-resistance in pancreatic cancer via SMARCC1
- (2013) Y Iwagami et al. BRITISH JOURNAL OF CANCER
- A Retrospective Study of Gemcitabine and Cisplatin Combination Therapy as Second-Line Treatment for Advanced Biliary Tract Cancer
- (2013) Takashi Sasaki et al. CHEMOTHERAPY
- Role of crosstalk between interleukin-6 and transforming growth factor-beta 1 in epithelial–mesenchymal transition and chemoresistance in biliary tract cancer
- (2013) Daisaku Yamada et al. EUROPEAN JOURNAL OF CANCER
- Metabolic Reprogramming: A Cancer Hallmark Even Warburg Did Not Anticipate
- (2012) Patrick S. Ward et al. CANCER CELL
- How cancer metabolism is tuned for proliferation and vulnerable to disruption
- (2012) Almut Schulze et al. NATURE
- Pyripyropene A, an Acyl–Coenzyme A:Cholesterol Acyltransferase 2–Selective Inhibitor, Attenuates Hypercholesterolemia and Atherosclerosis in Murine Models of Hyperlipidemia
- (2011) Taichi Ohshiro et al. ARTERIOSCLEROSIS THROMBOSIS AND VASCULAR BIOLOGY
- Development of molecularly targeted therapies in biliary tract cancers: Reassessing the challenges and opportunities
- (2011) Andrew X. Zhu et al. HEPATOLOGY
- Treatment of borderline cases for curative resection of biliary tract cancer
- (2011) Shogo Kobayashi et al. JOURNAL OF SURGICAL ONCOLOGY
- Gemcitabine alone or in combination with cisplatin in patients with biliary tract cancer: a comparative multicentre study in Japan
- (2010) T Okusaka et al. BRITISH JOURNAL OF CANCER
- Acyl-coenzyme A: Cholesterol acyltransferase inhibitor Avasimibe affect survival and proliferation of glioma tumor cell lines
- (2010) Sana Bemlih et al. CANCER BIOLOGY & THERAPY
- Cisplatin plus gemcitabine versus gemcitabine for biliary tract cancer
- (2010) Jochen Weigt et al. Expert Review of Gastroenterology & Hepatology
- Acyl-coenzyme A:cholesterol acyltransferases
- (2009) Ta-Yuan Chang et al. AMERICAN JOURNAL OF PHYSIOLOGY-ENDOCRINOLOGY AND METABOLISM
- High ACAT1 expression in estrogen receptor negative basal-like breast cancer cells is associated with LDL-induced proliferation
- (2009) Caryl J. Antalis et al. BREAST CANCER RESEARCH AND TREATMENT
- Gemcitabine alone or in combination with cisplatin in patients with advanced or metastatic cholangiocarcinomas or other biliary tract tumours: a multicentre randomised phase II study – The UK ABC-01 Study
- (2009) J W Valle et al. BRITISH JOURNAL OF CANCER
- Lipid Bodies Are Reservoirs of Cyclooxygenase-2 and Sites of Prostaglandin-E2 Synthesis in Colon Cancer Cells
- (2008) M. T. Accioly et al. CANCER RESEARCH
Find Funding. Review Successful Grants.
Explore over 25,000 new funding opportunities and over 6,000,000 successful grants.
ExplorePublish scientific posters with Peeref
Peeref publishes scientific posters from all research disciplines. Our Diamond Open Access policy means free access to content and no publication fees for authors.
Learn More